Discover the full insider trade history of UFP Technologies INC, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, UFP Technologies INC has published 54 public disclosures. Market capitalisation: €1.7bn. The latest transaction was disclosed on 13 May 2026 — Cession. Among the most active insiders: CROTEAU DANIEL C. All data is accessible without an account.
25 of 54 declarations
UFP Technologies, Inc. is a US-based industrial healthcare manufacturing company listed on the NASDAQ under the ticker UFPT. Headquartered in Newburyport, Massachusetts, United States, the company was founded in 1963 and has evolved from a protective packaging business into a specialized contract development and manufacturing organization. Today, it focuses primarily on single-use and single-patient medical devices, making it a niche supplier within the medical technology supply chain rather than a broad-based diversified manufacturer. The company’s core business centers on design, engineering, and manufacturing solutions for the medical market. Its products and components are used in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. In practical terms, UFP Technologies acts as an outsourcing partner to major medical-device OEMs, helping customers move from concept and design through industrialization, production, and delivery. This model tends to support sticky customer relationships, recurring program revenue, and a value proposition based on technical know-how rather than pure price competition. From a competitive standpoint, UFP Technologies benefits from specialization, application engineering, and a multi-site manufacturing footprint. The company describes itself as an important link in the medical-device supply chain and a valued outsourcing partner to many of the world’s leading medical-device manufacturers. That positioning creates meaningful barriers to entry, especially where customers require validated processes, materials expertise, regulatory discipline, and reliable transfer of production across facilities. Recent developments have been positive and strategically relevant. In 2025, UFP Technologies reported record full-year results, with strong growth in revenue and net income, and it continued to expand through targeted acquisitions. Management also highlighted new program launches and additional manufacturing capacity to support future growth. In early 2026, the company reported another solid quarter and said its recent acquisitions were performing well, with integrations essentially complete. Another key event for investors is leadership transition: the company announced that CEO R. Jeffrey Bailly is scheduled to retire at the annual meeting on June 4, 2026. For investors following Form 4 insider transactions, that combination of growth, acquisition activity, and succession planning is especially important to monitor.